Rectal cancer is a life-threatening disease worldwide. Chemotherapy resistance is common in rectal adenocarcinoma patients and has unfavorable survival outcomes; however, its related molecular mechanisms remain unknown. To identify genes related to the initiation and progression of rectal adenocarcinoma, three datasets were obtained from the Gene Expression Omnibus database. In total, differentially expressed genes were analyzed from 294 tumor and 277 paracarcinoma samples from patients with rectal cancer. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes functions were investigated. Cytoscape software and MicroRNA Enrichment Turned Network were applied to construct a protein-protein interaction network of the dependent hub genes and related microRNAs. The Oncomine database was used to identify hub genes. Additionally, Gene Expression Profiling Interactive Analysis was applied to determine the RNA expression level. Tumor immune infiltration was assessed using the Tumor Immune Estimation Resource database. The expression profiles of hub genes between stages, and their prognostic value, were also evaluated. During this study, data from The Cancer Genome Atlas were utilized. In rectal adenocarcinoma, four hub genes including CXCL1, CXCL2, CXCL3, and GNG4 were highly expressed at the gene and RNA levels. The expression of CXCL1, CXCL2, and CXCL3 was regulated by has-miR-1-3p and had a strong positive correlation with macrophage and neutrophil. CXCL2 and CXCL3 were differentially expressed at different tumor stages. High expression levels of CXCL1 and CXCL3 predicted poor survival. In conclusion, the CXCL1 and CXCL3 genes may have potential for prognosis and molecular targeted therapy of rectal adenocarcinoma.

BackgroundThis study aims to compare the efficacy and safety of neoadjuvant chemoradiotherapy (nCRT) with different radiotherapy doses (45Gy and 50.4Gy) in patients with locally advanced rectal cancer (LARC).MethodsHerein, 120 patients with LARC were retrospectively enrolled between January 2016 and June 2021. All patients underwent two courses of induction chemotherapy (XELOX), chemoradiotherapy, and total mesorectum excision (TME). A total of 72 patients received a radiotherapy dose of 50.4 Gy, while 48 patients received a dose of 45 Gy. Surgery was then performed within 5-12 weeks following nCRT.ResultsThere was no statistically significant difference between the baseline characteristics of the two groups. The rate of good pathological response in the 50.4Gy group was 59.72% (43/72), while in the 45Gy group achieved 64.58% (31/48) (P>0.05). The disease control rate (DCR) in the 50.4Gy group was 88.89% (64/72), compared to 89.58% (43/48) in the 45Gy group (P>0.05). The incidence of adverse reactions for radioactive proctitis, myelosuppression, and intestinal obstruction or perforation differed significantly between the two groups (P<0.05). The anal retention rate in the 50.4Gy group was significantly higher in contrast to the 45Gy group (P<0.05).ConclusionsPatients receiving a radiotherapy dose of 50.4Gy have a better anal retention rate but also a higher incidence of adverse events such as radioactive proctitis, myelosuppression, and intestinal obstruction or perforation, and a comparable prognosis to patients treated with a radiotherapy dose of 45Gy.

No abstract

Background and objectives: For patients with inoperable non-small cell lung cancer, concurrent chemoradiotherapy is the mainstay of treatment. At present, TMN stage is still the most commonly used clinical prediction model, but in the real world, patients with the same stage receive the same mode of treatment, their survival will be significantly different. The aim of our study was to look for predictors of patient survival in addition to TMN staging. If all kinds of predictors can be combined, the survival prediction of patients can be greatly improved and the clinical treatment and medication can be guided.Methods：The survival differences of 147 lung cancer patients receiving concurrent chemoradiotherapy were analyzed. Univariate and multivariate COX regression analysis were used to explore the relationship between blood markers before treatment and patient survival.Results: Univariate COX regression analysis showed that gender, hemoglobin, MCV, NLR, Smoking Index，IL-6 and SUA/SCr were significantly correlated with survival in patients receiving concurrent chemoradiotherapy. Multivariate COX regression analysis showed that IL-6 and SUA/SCr were prognostic factors for patients receiving radiotherapy and chemotherapy. According to receiver operating characteristic (ROC) curve analysis, the AUC of SUA/SCr and IL-6 were 0.757 and 0.770, respectively, and the optimal cutoff points of SUA/SCr and IL-6 were 3.99 and 4.79, respectively.Conclusions：Our study shows that gender, hemoglobin, MCV, NLR, Smoking Index，SUA/SCr and IL-6 are related to survival of lung cancer patients. Il-6 and SUA/SCr are effective predictors of survival in lung cancer patients.

Background and objectives: After receiving radical concurrent radiotherapy and chemotherapy, some patients with laryngeal cancer still have recurrence, and the recurrence time of different patients is different, which will pose a threat to the quality of life and survival of patients. The purpose of our study is to find out the factors that can predict the recurrence of laryngeal cancer, provide more accurate and individualized treatment for patients with laryngeal cancer, and improve the quality of life of patients.Methods：We collected follow-up data from 123 patients with laryngeal cancer who were admitted to the First Affiliated Hospital of Wenzhou Medical University between 2010 and 2015. These patients received only radical concurrent chemoradiotherapy after diagnosis. Univariate Cox analysis was used to find the factors related to Progression-free survival（PFS）in patients with laryngeal cancer. Multivariate Cox regression analysis was used to determine the factors and indicators that could predict patients' PFS. The Receiver Operating Characteristic curve（ROC curve） was used to determine the optimal truncation value of the forecast index.Results：Univariate Cox regression analysis showed that HPV, lymph node metastasis, NLR, （lymphocyte-to-monocyte Ratio）LMR and white blood cell count were related to PFS in patients with laryngeal cancer. Multivariate Cox regression analysis showed that positive HPV and NLR were effective predictors of PFS in laryngeal cancer. According to the ROC curve, the area under the curve of NLR is 0.743, and the optimal truncation value is 2.26.Conclusions：HPV and NLR are reliable predictors of PFS in patients with laryngeal cancer receiving concurrent chemoradiotherapy, which can provide help and suggestions for follow-up and individualized treatment of laryngeal cancer after treatment.

Background: The research aimed to evaluate the efficacy and safety of different radiation doses (45Gy and 50.4Gy) on neoadjuvant in patients with LARC.Methods: Patients with LARC between January 2016 and June 2021 were retrospectively enrolled in the study, all of them underwent neoadjuvant chemoradiotherapy and radical surgical. XELOX regimen was administered for two cycles before nCRT. 72 patients received radiation dose with 50.4Gy while 45 patients with 45Gy. During radiotherapy, concurrent chemotherapy was employed as capecitabine alone. Surgery was performed within 5-12 weeks after nCRT.Results: Baseline characteristics in both groups were not statistically significant. The rate of well pathological regression in the 50.4Gy group was 59.72% (43/72) while in the 45Gy group was 64.58% (31/48) (P>0.05). The rate of radiographic remission in the 50.4Gy group was 70.83% (51/72), compared with 68.75% (33/48) in the 45Gy group(P>0.05). Significant differences existed in the incidence of several adverse events (radioactive proctitis, myelosuppression and intestinal obstruction or perforation) between the 50.4Gy group and the 45Gy group(P<0.05).Conclusions: Higher radiation dose could increase the incidence of several adverse events, meanwhile, it failed to improve the rate of pathological regression and imaging remission.